FDA grants rolling submission to Luveniq for lupus nephritis.- Aurinia Pharmaceuticals
Related news and insights
Aurinia Pharmaceuticals Inc. has announced that the Company’s licensing partner, Otsuka Pharmaceutical Europe Ltd. , filed an initial Marketing Authorization Application (MAA) for voclosporin for the treatment of lupus nephritis (LN) to the European Medicines Agency (EMA).
Aurinia Pharmaceuticals Inc. presented an analysis of its Phase III AURORA 1 study data at the European Renal Association – European Dialysis and Transplant Association (ERA-EDTA) 2021 Congress .
Aurinia Pharmaceuticals Inc. announced that The Lancet, an international, peer-reviewed medical journal, published the results of the Company’s Phase III AURORA 1 study evaluating Lupkynis (voclosporin) in adults with lupus nephritis (LN).